Present and Future Bounds on Non-Standard Neutrino Interactions

We consider Non-Standard neutrino Interactions (NSI), described by four-fermion operators of the form $(\bar{\nu}_{\alpha} \gamma {\nu}_{\beta}) (\bar{f} \gamma f)$, where $f$ is an electron or first generation quark. We assume these operators are generated at dimension $\geq 8$, so the related vertices involving charged leptons, obtained by an SU(2) transformation $\nu_{\delta} \to e_{\delta}$, do not appear at tree level. These related vertices necessarily arise at one loop, via $W$ exchange. We catalogue current constraints from $\sin^2 \theta_W$ measurements in neutrino scattering, from atmospheric neutrino observations, from LEP, and from bounds on the related charged lepton operators. We estimate future bounds from comparing KamLAND and solar neutrino data, and from measuring $\sin^2 \theta_W$ at the near detector of a neutrino factory. Operators constructed with $\nu_\mu$ and $\nu_e$ should not confuse the determination of oscillation parameters at a $\nu$factory, because the processes we consider are more sensitive than oscillations at the far detector. For operators involving $\nu_\tau$, we estimate similar sensitivities at the near and far detector.Comment: Erratum added at the end of the documen

The "Birmingham stitch"--avoiding slippage in laparoscopic gastric banding.

BACKGROUND Slippage rates of 1.4-24 % are frequently quoted after adjustable gastric banding. This complication can be extremely serious and has contributed to many units offering more invasive interventions in the surgical management of morbid obesity. We present results of the first 1,140 Laparoscopic Bands performed in our unit. METHODS Between April 2003 and June 2007, 1140 consecutive patients, mean weight 121.5 kg (range 73-268 kg), mean body mass index (BMI) 44.3 kg/m(2) (range 35-88) underwent laparoscopic adjustable gastric banding (LAGB). An identical surgical technique of one gastropexy suture in addition to the two routine gastro-gastro tunnel sutures was used in all cases. Fluoroscopy-guided adjustments were performed at 3 and 6 months and fluoroscopic evaluations were performed later if clinically indicated. RESULTS There was no mortality and only one major septic complication of gastric perforation 1 week postoperatively which was managed conservatively. The mean stay was 1.02 days (range 0-30 days). Excess percent BMI loss in these patients at 3, 6, 12, 18, 24, 30, and 36 months were 25.4%, 34.7%, 38.3%, 41.1%, 43.7%, 44.4%, and 58.9%, respectively. Slippage with urgent readmission occurred in one patient (0.08%) at 5 months. Two partial slippages were noticed at 12 and 18 months, respectively. One patient had the band removed and the other was treated by band deflation and repositioning 6 months later. CONCLUSION These results demonstrate that in our unit, laparoscopic gastric band insertion is successful in producing weight loss and at the same time has a very low slippage and pouch dilatation rate. This difference is most probably secondary to operative technique

mGluR5 Modulation of Behavioral and Epileptic Phenotypes in a Mouse Model of Tuberous Sclerosis Complex

Drugs targeting metabotropic glutamate receptor 5 (mGluR5) have therapeutic potential in autism spectrum disorders (ASD), including tuberous sclerosis complex (TSC). The question whether inhibition or potentiation of mGluR5 could be beneficial depends, among other factors, on the specific indication. To facilitate the development of mGluR5 treatment strategies, we tested the therapeutic utility of mGluR5 negative and positive allosteric modulators (an mGluR5 NAM and PAM) for TSC, using a mutant mouse model with neuronal loss of Tsc2 that demonstrates disease-related phenotypes, including behavioral symptoms of ASD and epilepsy. This model uniquely enables the in vivo characterization and rescue of the electrographic seizures associated with TSC. We demonstrate that inhibition of mGluR5 corrects hyperactivity, seizures, and elevated de novo synaptic protein synthesis. Conversely, positive allosteric modulation of mGluR5 results in the exacerbation of hyperactivity and epileptic phenotypes. The data suggest a meaningful therapeutic potential for mGluR5 NAMs in TSC, which warrants clinical exploration and the continued development of mGluR5 therapies